Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial.

Devanand DP, Andrews H, Kreisl WC, Razlighi Q, Gershon A, Stern Y, Mintz A, Wisniewski T, Acosta E, Pollina J, Katsikoumbas M, Bell KL, Pelton GH, Deliyannides D, Prasad KM, Huey ED.

BMJ Open. 2020 Feb 6;10(2):e032112. doi: 10.1136/bmjopen-2019-032112.

2.

HIV-Negative Cryptococcal Meningoencephalitis Results in a Persistent Frontal-Subcortical Syndrome.

Traino K, Snow J, Ham L, Summers A, Segalà L, Shirazi T, Biassou N, Panackal A, Anjum S, Marr KA, Kreisl WC, Bennett JE, Williamson PR.

Sci Rep. 2019 Dec 5;9(1):18442. doi: 10.1038/s41598-019-54876-7.

3.

Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment.

Zou J, Tao S, Johnson A, Tomljanovic Z, Polly K, Klein J, Razlighi QR, Brickman AM, Lee S, Stern Y, Kreisl WC.

Neurobiol Aging. 2020 Jan;85:11-21. doi: 10.1016/j.neurobiolaging.2019.09.019. Epub 2019 Sep 29.

PMID:
31698286
4.

Intact global cognitive and olfactory ability predicts lack of transition to dementia.

Devanand DP, Lee S, Luchsinger JA, Andrews H, Goldberg T, Huey ED, Schupf N, Manly J, Stern Y, Kreisl WC, Mayeux R.

Alzheimers Dement. 2020 Feb;16(2):326-334. doi: 10.1016/j.jalz.2019.08.200. Epub 2020 Jan 4.

PMID:
31676234
5.

Neuroinflammation in frontotemporal lobar degeneration revealed by 11 C-PBR28 PET.

Kim MJ, McGwier M, Jenko KJ, Snow J, Morse C, Zoghbi SS, Pike VW, Innis RB, Kreisl WC.

Ann Clin Transl Neurol. 2019 Jul;6(7):1327-1331. doi: 10.1002/acn3.50802. Epub 2019 Jun 17.

6.

FDG-PET patterns associated with underlying pathology in corticobasal syndrome.

Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM, Nobili F, Ghetti B, Grafman J.

Neurology. 2019 Mar 5;92(10):e1121-e1135. doi: 10.1212/WNL.0000000000007038. Epub 2019 Jan 30.

7.

Automatic Extraction of a Reference Region for the Noninvasive Quantification of Translocator Protein in Brain Using 11C-PBR28.

Zanotti-Fregonara P, Kreisl WC, Innis RB, Lyoo CH.

J Nucl Med. 2019 Jul;60(7):978-984. doi: 10.2967/jnumed.118.222927. Epub 2019 Jan 17.

8.

Building a database for brain 18 kDa translocator protein imaged using [11C]PBR28 in healthy subjects.

Paul S, Gallagher E, Liow JS, Mabins S, Henry K, Zoghbi SS, Gunn RN, Kreisl WC, Richards EM, Zanotti-Fregonara P, Morse CL, Hong J, Kowalski A, Pike VW, Innis RB, Fujita M.

J Cereb Blood Flow Metab. 2019 Jun;39(6):1138-1147. doi: 10.1177/0271678X18771250. Epub 2018 May 11.

PMID:
29749279
9.

Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults.

Kreisl WC, Jin P, Lee S, Dayan ER, Vallabhajosula S, Pelton G, Luchsinger JA, Pradhaban G, Devanand DP.

J Alzheimers Dis. 2018;62(4):1759-1766. doi: 10.3233/JAD-170960.

10.

Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia.

Kreisl WC, Henter ID, Innis RB.

Adv Pharmacol. 2018;82:163-185. doi: 10.1016/bs.apha.2017.08.004. Epub 2017 Nov 10. Review.

11.

Non-invasive estimation of [11C]PBR28 binding potential.

Schain M, Zanderigo F, Ogden RT, Kreisl WC.

Neuroimage. 2018 Apr 1;169:278-285. doi: 10.1016/j.neuroimage.2017.12.002. Epub 2017 Dec 5.

PMID:
29203457
12.

Discerning the relationship between microglial activation and Alzheimer's disease.

Kreisl WC.

Brain. 2017 Jul 1;140(7):1825-1828. doi: 10.1093/brain/awx151. No abstract available.

PMID:
29177498
13.

Neuroinflammation in Neurodegenerative Disorders-a Review.

Schain M, Kreisl WC.

Curr Neurol Neurosci Rep. 2017 Mar;17(3):25. doi: 10.1007/s11910-017-0733-2. Review.

PMID:
28283959
14.

11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.

Kreisl WC, Lawrence R, Page E, Teich AF, Subramaniam DS, Innis RB, Turner RS.

Neurology. 2017 Mar 7;88(10):1001-1004. doi: 10.1212/WNL.0000000000003693. Epub 2017 Feb 8. No abstract available.

15.

Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease.

Kreisl WC, Lyoo CH, Liow JS, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS, Innis RB.

Neurobiol Aging. 2017 Mar;51:132-140. doi: 10.1016/j.neurobiolaging.2016.12.006. Epub 2016 Dec 16.

16.

Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series.

Devanand DP, Pelton GH, D'Antonio K, Strickler JG, Kreisl WC, Noble J, Marder K, Skomorowsky A, Huey ED.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):73-75. doi: 10.1097/WAD.0000000000000161. No abstract available.

17.

(11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease.

Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS, Innis RB.

Neurobiol Aging. 2016 Aug;44:53-61. doi: 10.1016/j.neurobiolaging.2016.04.011. Epub 2016 Apr 27.

18.

(18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.

Liow JS, Zoghbi SS, Hu S, Hall MD, Hines CS, Shetty HU, Araneta MD, Page EM, Pike VW, Kreisl WC, Herscovitch P, Gottesman MM, Theodore WH, Innis RB.

Neuroimage. 2016 Sep;138:134-140. doi: 10.1016/j.neuroimage.2016.05.045. Epub 2016 May 19.

19.

Neuroinflammation in Temporal Lobe Epilepsy Measured Using Positron Emission Tomographic Imaging of Translocator Protein.

Gershen LD, Zanotti-Fregonara P, Dustin IH, Liow JS, Hirvonen J, Kreisl WC, Jenko KJ, Inati SK, Fujita M, Morse CL, Brouwer C, Hong JS, Pike VW, Zoghbi SS, Innis RB, Theodore WH.

JAMA Neurol. 2015 Aug;72(8):882-8. doi: 10.1001/jamaneurol.2015.0941. Erratum in: JAMA Neurol. 2015 Aug;72(8):950.

20.

Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein.

Lyoo CH, Ikawa M, Liow JS, Zoghbi SS, Morse CL, Pike VW, Fujita M, Innis RB, Kreisl WC.

J Nucl Med. 2015 May;56(5):701-6. doi: 10.2967/jnumed.114.146027. Epub 2015 Mar 12.

21.

Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.

Kreisl WC, Bhatia R, Morse CL, Woock AE, Zoghbi SS, Shetty HU, Pike VW, Innis RB.

J Nucl Med. 2015 Jan;56(1):82-7. doi: 10.2967/jnumed.114.146894. Epub 2014 Dec 11.

22.

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.

Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB; Biomarkers Consortium PET Radioligand Project Team.

Brain. 2013 Jul;136(Pt 7):2228-38. doi: 10.1093/brain/awt145. Epub 2013 Jun 17.

23.

A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation.

Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, Zoghbi SS, Hyde T, Kleinman JE, Pike VW, McMahon FJ, Innis RB; Biomarkers Consortium PET Radioligand Project Team.

J Cereb Blood Flow Metab. 2013 Jan;33(1):53-8. doi: 10.1038/jcbfm.2012.131. Epub 2012 Sep 12.

24.

The neurobiology of Alzheimer disease defined by neuroimaging.

Masdeu JC, Kreisl WC, Berman KF.

Curr Opin Neurol. 2012 Aug;25(4):410-20. doi: 10.1097/WCO.0b013e3283557b36. Review.

PMID:
22766722
25.

Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy.

Hirvonen J, Kreisl WC, Fujita M, Dustin I, Khan O, Appel S, Zhang Y, Morse C, Pike VW, Innis RB, Theodore WH.

J Nucl Med. 2012 Feb;53(2):234-40. doi: 10.2967/jnumed.111.091694. Epub 2012 Jan 11.

26.

Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.

Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, Zhang Y, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2593-8. doi: 10.1073/pnas.1014641108. Epub 2011 Jan 24.

27.

Mixed-affinity binding in humans with 18-kDa translocator protein ligands.

Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, Innis RB, Pike VW, Reynolds R, Matthews PM, Parker CA.

J Nucl Med. 2011 Jan;52(1):24-32. doi: 10.2967/jnumed.110.079459. Epub 2010 Dec 13.

28.

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB.

J Nucl Med. 2010 Apr;51(4):559-66. doi: 10.2967/jnumed.109.070151. Epub 2010 Mar 17.

29.

Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker.

Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P, Hong J, Morse CL, Zoghbi SS, Gladding RL, Jacobson S, Oh U, Pike VW, Innis RB.

Neuroimage. 2010 Feb 15;49(4):2924-32. doi: 10.1016/j.neuroimage.2009.11.056. Epub 2009 Dec 4.

30.

Stroke incidentally identified using improved positron emission tomography for microglial activation.

Kreisl WC, Mbeo G, Fujita M, Zoghbi SS, Pike VW, Innis RB, McArthur JC.

Arch Neurol. 2009 Oct;66(10):1288-9. doi: 10.1001/archneurol.2009.208. No abstract available.

31.

Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET.

Brown AK, Kimura Y, Zoghbi SS, Siméon FG, Liow JS, Kreisl WC, Taku A, Fujita M, Pike VW, Innis RB.

J Nucl Med. 2008 Dec;49(12):2042-8. doi: 10.2967/jnumed.108.056291.

Supplemental Content

Loading ...
Support Center